DENTSPLY SIRONA Inc. $XRAY Shares Acquired by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY grew its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 24.1% in the first quarter, Holdings Channel.com reports. The firm owned 2,977,200 shares of the medical instruments supplier’s stock after acquiring an additional 578,700 shares during the quarter. DENTSPLY SIRONA makes up approximately 1.3% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 21st biggest position. Paradigm Capital Management Inc. NY’s holdings in DENTSPLY SIRONA were worth $34,536,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter valued at $26,000. Goldman Sachs Group Inc. increased its stake in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after acquiring an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth boosted its position in shares of DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 9,355 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on XRAY. Weiss Ratings lowered shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. UBS Group cut their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Barclays cut their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Thursday, June 4th. Citigroup initiated coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on DENTSPLY SIRONA in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price objective for the company. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.42.

Insider Activity

In other DENTSPLY SIRONA news, Director Brian P. Mckeon purchased 10,000 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was bought at an average price of $10.12 per share, with a total value of $101,200.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $101,200. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brian T. Gladden purchased 9,985 shares of the company’s stock in a transaction on Monday, June 15th. The stock was acquired at an average price of $10.02 per share, with a total value of $100,049.70. Following the purchase, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This represents a 19.25% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by company insiders.

DENTSPLY SIRONA Stock Up 1.7%

Shares of NASDAQ XRAY opened at $12.93 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The business’s 50 day moving average is $11.08 and its two-hundred day moving average is $11.81. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $16.59. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of -4.10, a PEG ratio of 1.51 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The company’s quarterly revenue was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.